1.1 	A resolution
1.2 	memorializing the Congress of the United States to direct the United States Food and 
1.3 	Drug Administration to conduct trials for medical marijuana research.
1.4 	WHEREAS, there is a need for additional comprehensive and well-controlled studies on the 
1.5 	effectiveness of using marijuana and related cannabinoids to treat patients who have serious 
1.6 	conditions; and
1.7 	WHEREAS, preclinical, anecdotal, and controlled evidence suggests the possible efficacy 
1.8 	of marijuana and related cannabinoid treatment, and that the application of such evidence could 
1.9 	enhance the understanding and treatment of disease; and
1.10 	WHEREAS, marijuana is currently classified by the United States Drug Enforcement 
1.11 	Administration as a federal Schedule I controlled substance, thereby restricting medical use research; 
1.12 	and
1.13 	WHEREAS, it is important to enable researchers to conduct more clinical and public health 
1.14 	research with the purpose of developing cannabinoid-based medicines, specifically allowing for 
1.15 	randomized clinical trials and alternative delivery methods;  NOW, THEREFORE,
1.16 	BE IT RESOLVED by the Legislature of the State of Minnesota that it urges the President 
1.17 	and the Congress of the United States to direct the United States Food and Drug Administration to 
1.18 	approve randomized clinical trials for medicinal use of marijuana.
1.19 	BE IT FURTHER RESOLVED that the Secretary of State of the State of Minnesota is directed 
1.20 	to prepare copies of this memorial and transmit them to the President of the United States, the 
1.21 	President and the Secretary of the United States Senate, the Speaker and the Clerk of the United 
1.22 	States House of Representatives, the chair of the United States Senate Committee on Finance, the 
1.23 	chair of the United States House Committee on Ways and Means, and Minnesota's Senators and 
1.24 	Representatives in Congress.